Skip to main content

1 Result(s)

within J. Beckman Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

    Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics ...

    Erica L. Mayer, M. E. Scheulen, J. Beckman… in Breast Cancer Research and Treatment (2013)